Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

(2021) Thierry Conroy et al.   LANCET ONCOLOGY

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

(2021) Emmanouil Fokas et al.   JAMA Oncology

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

(2020) Al B. Benson et al.   Journal of the National Comprehensive Cancer Network

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

(2020) Renu R Bahadoer et al.   LANCET ONCOLOGY

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12

(2019) Emmanouil Fokas et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study

(2018) Maxime J M van der Valk et al.   LANCET

Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

(2018) Andrea Cercek et al.   JAMA Oncology

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial

(2015) C. Fernandez-Martos et al.   ANNALS OF ONCOLOGY

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

(2015) J. Joshua Smith et al.   BMC CANCER

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

(2015) Carmen J. Allegra et al.   JNCI-Journal of the National Cancer Institute

Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial

(2015) Julio Garcia-Aguilar et al.   LANCET ONCOLOGY

High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study

(2015) Ane L Appelt et al.   LANCET ONCOLOGY

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

(2015) Claus Rödel et al.   LANCET ONCOLOGY

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

(2015) Carmen J. Allegra et al.   JNCI-Journal of the National Cancer Institute

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

(2012) Jean-Pierre Gérard et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

(2010) Monique Maas et al.   LANCET ONCOLOGY

Interval Between Surgery and Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Does Delayed Surgery Have an Impact on Outcome?

(2008) Angelita Habr-Gama et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS